Literature DB >> 12943489

Recurrent duodenal ulcer haemorrhage: a pharmacoeconomic comparison of various management strategies.

Uday Chand Ghoshal1, Rakesh Aggarwal, Chalamalasetty Sreenivasa Baba.   

Abstract

BACKGROUND: Duodenal ulcer (DU) bleeding has a 7 - 13% mortality rate and bleeding often recurs. Prevention of recurrence is, therefore, an important goal. Eradication of Helicobacter pylori or maintenance treatment with a proton pump inhibitor (PPI) may reduce recurrent DU bleeding. Economic comparison of these options is sparse.
METHODS: After the control of index bleeding with endotherapy and drugs, three strategies were evaluated: empirical treatment for possible H. pylori infection followed by a PPI for 2 months; test for H. pylori, eradication if positive, maintenance PPI if negative; maintenance PPI alone. Probability and direct cost data were obtained from a Medline search and Indian hospitals, respectively. Cost-minimisation, cost-utility, one- and two-way sensitivity analyses and threshold values were evaluated.
RESULTS: Treatment of H. pylori, particularly empirical, was the preferred strategy and dominated maintenance treatment with PPI. The test-and-treat strategy was better than the empirical treatment strategy only when the probabilities of H. pylori eradication, ulcer healing following eradication and of frequency of H. pylori infection in bleeding DU were less than 58, 73 and 58%, respectively.
CONCLUSIONS: Eradication of H. pylori is preferred in preventing recurrent bleeding from DU.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12943489     DOI: 10.1517/14656566.4.9.1593

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  1 in total

Review 1.  Efficiency of Diagnostic Testing for Helicobacter pylori Infections-A Systematic Review.

Authors:  Paula Rojas García; Simon van der Pol; Antoinette D I van Asselt; Maarten Postma; Roberto Rodríguez-Ibeas; Carmelo A Juárez-Castelló; Marino González; Fernando Antoñanzas
Journal:  Antibiotics (Basel)       Date:  2021-01-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.